Nome Químico: 6α,9-Difluoro-17-[[(fluoromethyl)sulphanyl]carbonyl]-11β-hydroxy-16α-methyl-3-oxoandrosta-1,4-dien-17α-yl 6α,9-difluoro-11β,17-dihydroxy-16α-methyl-3-oxoandrosta-1,4-diene-17β-carboxylate ;
Sinônimo: Fluticasone Furoate EP Impurity K ; Fluticasone USP Related Compound E ; Fluticasone Dimer Impurity ;
Sorrisos: C[C@@]12[C@](C(O[C@]3(C(SCF)=O)[C@H](C)C[C@@]4([H])[C@]5([H])C[C@H](F)C6=CC(C=C[C@]6(C)[C@@]5(F)[C@@H](O)C[C@]34C)=O)=O)(O)[C@H](C)C[C@@]1([H])[C@]7([H])C[C@H](F)C8=CC(C=C[C@]8(C)[C@@]7(F)[C@@H](O)C2)=O
Inchi: InChI=1S/C25H29F3O5S/c1-5-20(31)33-25(21(32)34-12-26)13(2)8-15-16-10-18(27)17-9-14(29)6-7-22(17,3)24(16,28)19(30)11-23(15,25)4/h6-7,9,13,15-16,18H,5,8,10-12H2,1-4H3/t13-,15+,16+,18+,22+,23+,24+,25+/m1/s1
Characterisation of impurities in bulk drug batches of fluticasone propionate using directly coupled HPLC–NMR spectroscopy and HPLC–MS
Nisha Mistry a , Ismail M. Ismail b , Marco S. Smith c , Jeremy K. Nicholson d , John C. Lindon
Journal of Pharmaceutical and Biomedical Analysis 16 (1997) 697–705